OBJECTIVE: To describe the pharmacodynamic profile of daptomycin against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci species based on bacterial density in an immunocompromised mouse thigh infection model. MATERIALS AND METHODS: The pharmacodynamic (PD) profile of daptomycin was determined against two MRSA, one vancomycin-resistant Enterococcus faecium, and one vancomycin-susceptible Enterococcus faecalis using the immunocompromised murine thigh model. Efficacy was assessed by the change in log10 cfu in thighs after 24 h of drug treatment. RESULTS: Daptomycin produced a maximal kill of 4.5-5 log10 cfu against the MRSA and 1.5-2 log10 for the Enterococcus species. AUC/MIC was the most predictive of the PD parameters. Utilizing MICs determined in serum or broth in the calculation of the PD parameters had minimal effect on this correlation. AUCfree/MICbroth required for static effects with MRSA and Enterococcus species were 12-36 and 5-13, whereas 99% of maximal kill was achieved at ratios of 171-442 and 38-157, respectively. CONCLUSIONS: These data reveal the potent in vivo bactericidal activity of daptomycin against MRSA and Enterococcus species using clinically achievable drug exposures (dose 4-6 mg/kg per day) currently under investigation in man.
OBJECTIVE: To describe the pharmacodynamic profile of daptomycin against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci species based on bacterial density in an immunocompromised mouse thigh infection model. MATERIALS AND METHODS: The pharmacodynamic (PD) profile of daptomycin was determined against two MRSA, one vancomycin-resistant Enterococcus faecium, and one vancomycin-susceptible Enterococcus faecalis using the immunocompromised murine thigh model. Efficacy was assessed by the change in log10 cfu in thighs after 24 h of drug treatment. RESULTS:Daptomycin produced a maximal kill of 4.5-5 log10 cfu against the MRSA and 1.5-2 log10 for the Enterococcus species. AUC/MIC was the most predictive of the PD parameters. Utilizing MICs determined in serum or broth in the calculation of the PD parameters had minimal effect on this correlation. AUCfree/MICbroth required for static effects with MRSA and Enterococcus species were 12-36 and 5-13, whereas 99% of maximal kill was achieved at ratios of 171-442 and 38-157, respectively. CONCLUSIONS: These data reveal the potent in vivo bactericidal activity of daptomycin against MRSA and Enterococcus species using clinically achievable drug exposures (dose 4-6 mg/kg per day) currently under investigation in man.
Authors: Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: Nimish Patel; Katie Cardone; Darren W Grabe; Shari Meola; Christopher Hoy; Harold Manley; George L Drusano; Thomas P Lodise Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191
Authors: C Andrew DeRyke; Christina Sutherland; Bo Zhang; David P Nicolau; Joseph L Kuti Journal: Antimicrob Agents Chemother Date: 2006-11 Impact factor: 5.191
Authors: Mohamed A Ibrahim; Arsala A Mansoor; Amanda Gross; M Khalid Ashfaq; Melissa Jacob; Shabana I Khan; Mark T Hamann Journal: J Nat Prod Date: 2009-12 Impact factor: 4.050
Authors: Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson Journal: J Antimicrob Chemother Date: 2010-04-02 Impact factor: 5.790
Authors: John F Mohr; Luis Ostrosky-Zeichner; David J Wainright; Donald H Parks; Timothy C Hollenbeck; Charles D Ericsson Journal: Antimicrob Agents Chemother Date: 2008-02-25 Impact factor: 5.191